Houston-based Castle Biosciences Inc., a molecular diagnostics company with a focus on treating cancer, has just revealed its resolution of financing worth $11.8 million. This round of funding was primarily the result of the company’s latest investor, HealthQuest Capital, as well as contributions from pre-existing investors Mountain Group Capital and Affiliates and Longfellow Venture Partners, among others who took part in the funding round. The company also announced a new member of the Board of Directors — Garheng Kong, M.D., Ph.D., HealthQuest Capital’s Managing Partner.

The new funding will be used for improving accessibility to the company’s wide range of groundbreaking diagnostic tests, along with DecisionDx-Melanoma, a diagnostic tool designed to detect risk of metastasis in patients diagnosed with melanoma.